How Does the Mounjaro Injection Work for Weight Loss?

What exactly is happening inside the body when you inject Mounjaro?

Tirzepatide, the active molecule in Mounjaro, is a synthetic peptide designed to mimic two hormones the gut releases naturally after eating: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Both are incretins, chemical messengers whose job includes signalling to the brain that food has arrived. Mounjaro binds to and activates both receptors at the same time, which is why it is described as a dual agonist.

GLP-1 receptor activation slows the rate at which the stomach empties, so a smaller meal produces a longer-lasting feeling of fullness. It also acts on appetite centres in the hypothalamus, reducing the intensity of hunger signals between meals. GIP adds a second layer: animal and human studies suggest it acts on fat tissue and on reward-related brain circuits involved in food motivation, though researchers are still characterising exactly how that translates into weight loss in people. The NHS medicines page for tirzepatide explains this dual mechanism in terms written for patients, and it is worth reading alongside your prescriber's advice.

One practical consequence of gastric slowing is that the nausea many people notice early in treatment (particularly after a dose increase) is a direct result of this mechanism at work, not a sign that something has gone wrong. The body adapts over days to a few weeks for most people. If you want to understand in more detail how the Mounjaro injection works at a biological level, that tends to make the nausea more manageable once you can see why it happens.

The injection itself is subcutaneous: a short needle delivers tirzepatide into the fatty tissue just beneath the skin, from where it is absorbed slowly into the bloodstream over the week until the next dose. Details on the most effective injection sites for Mounjaro (abdomen, thigh and upper arm) are covered separately, along with technique tips.

Why does the dual GIP and GLP-1 approach produce more weight loss than a single pathway?

This is a question our prescribers hear most weeks, and it gets to the heart of what makes tirzepatide different from earlier weight-loss injections. GLP-1-only medicines (such as semaglutide, the active ingredient in Wegovy) work well. Adding GIP activation appears to amplify the appetite-suppressing signal beyond what either hormone achieves alone.

The clearest evidence comes from SURMOUNT-1, a 72-week randomised controlled trial published in the New England Journal of Medicine, in which adults taking tirzepatide 15mg lost an average of around 20–21% of their body weight compared with placebo. Subsequent head-to-head data from the SURMOUNT-5 trial, also published in the NEJM in 2025, found tirzepatide produced greater average weight reduction than semaglutide 2.4mg over the same period, with NICE's appraisal committee noting the indirect comparisons also favour tirzepatide. None of that means it is the right choice for every person; individual response varies, and a prescriber considers far more than the trial averages.

It is also worth being clear about what the mechanism does not do. Mounjaro does not burn fat directly, speed up metabolism in any simple sense, or override the body's energy systems completely. What it does is lower the biological drive to eat, which makes it substantially easier to maintain a reduced-calorie diet, the kind that produces sustained weight loss over months. Lifestyle changes alongside treatment remain part of how it is licensed. More background on what Mounjaro is used for puts this in the broader clinical context.

Does the mechanism change as the dose increases?

The core dual-receptor action stays the same at every dose level; what changes is intensity. Mounjaro is available in six strengths (2.5, 5, 7.5, 10, 12.5 and 15 mg) and treatment always begins at 2.5 mg. That starting dose is a tolerability step: the body adjusts to slowed gastric emptying before the therapeutic effect builds. The prescriber then increases the dose in steps, typically every four weeks, guided by how well the treatment is tolerated and how weight loss is progressing.

Each increase sharpens the appetite-suppressing signal, which is why weight loss often accelerates as titration progresses and why side effects can briefly resurface after a step up. The prescriber's job is to find the highest dose that delivers meaningful results without making day-to-day life difficult. Patients should not adjust their own dose or timing, the Patient Information Leaflet and prescriber are the right sources for those decisions.

Storage matters too, because the mechanism depends on the medicine arriving intact: Mounjaro pens need refrigerating at 2–8°C. The exact room-temperature allowance is stated in the SmPC; your prescriber or the leaflet inside the pen box is the place to check that, not a general article. Practical guidance on how to use Mounjaro correctly covers handling and technique in full.

If you are wondering whether this mechanism makes you eligible for treatment, the Mounjaro overview page sets out the UK licensing criteria and how a clinical assessment works. Cost is a reasonable question too, a straightforward breakdown of what private treatment involves is on the Mounjaro prices page. And if you are ready to talk through your own situation with a prescriber, checking your eligibility is the natural next step.